Diabetes and atypical antipsychotic agents John Newcomer (St. Louis, MO) discussed changes in adiposity and insulin sensitivity with the atypical antipsychotic agents ziprasidone, risperidone, aripiprazole, quetiapine, clozapine, and olanzapine, addressing the diabetes risk seen during treatment. Among persons with schizophrenia, approximately half are obese, half to three-quarters smoke, 10 -14% have diabetes, particularly with coexisting depression, and there are also increased prevalences of hypertension and dyslipidemia. Metabolic syndrome, Newcomer stated, is present in ϳ40% of persons with schizophrenia. Persons with schizophrenia have increased rates of cardiovascular disease (CVD). The mortality due to myocardial infarction is 19% greater among persons with any mental illness and is 34% greater among persons with schizophrenia (1) than in a control population. CVD, then, is of similar importance to suicide as a cause of death in these patients, whose overall mortality is increased by half, leading to a 20% shorter lifespan than in persons without schizophrenia (2) .
A major issue is weight gain with the atypical antipsychotic agents. Although weight gain occurs with conventional antipsychotic agents such as haloperidol, greater weight gain definitely occurs with chlorpromazine, olanzapine, and clozapine and may occur with risperidone and quetiapine. A meta-analysis of weight change during randomized, controlled, 10-week trials showed that olanzapine and clozapine were associated with a 4-kg weight gain, while haloperidol and risperidone were associated with a 2-kg weight gain (3) . Quetiapine leads to ϳ4-fold and olanzapine ϳ10-fold weight gain, while other antipsychotic agents give 2-fold greater rates of weight gain than those seen in nontreated schizophrenic persons. In 1-year studies, ziprasidone, risperidone, quetiapine, and olanzapine are associated with weight gains of ϳ1, 2, 4, and 6 kg. The degree of weight gain appears to be dose related, with olanzapine doses Ͼ10 mg daily associated with a 12-kg weight gain. These figures appear to be confirmed by randomized controlled trials comparing aripiprazole with olanzapine, showing weight loss with the former (perhaps because of withdrawal of prior drugs that had caused weight gain) and weight gain with the latter agent. Initial studies also show weight loss with ziprasidone treatment when changing to this agent from olanzapine or, to a lesser extent, from risperidone. In contrast, discontinuing high-potency conventional antipsychotic agents does not lead to significant weight change.
An important metabolic consequence of the use of these agents is diabetes, and there is some evidence that new-onset diabetes in this setting may also occur in the absence of weight gain. Animal models show dose-dependent worsening in insulin sensitivity with atypical antipsychotic agent administration, further suggesting that increases in fat mass alone may not fully explain the findings. The Food and Drug Administration's Medwatch program and published cases report development of ketoacidosis in some cases, suggesting the potential of serious metabolic derangement, with a warning label to this effect now included in the package inserts for all the atypical antipsychotic agents (4) .
In an analysis of an Iowa Medicaid database of persons with schizophrenia followed during 1990 -1998, 552 persons treated with clozapine were comp a r e d w i t h 2 , 4 6 1 t r e a t e d w i t h conventional antipsychotic drugs, with persons using other atypical antipsychotic agents and those with baseline diabetes, dyslipidemia, and hypertension excluded from the analysis (5) . Diabetes, hyperlipidemia, and hypertension showed no difference in the overall group, but among persons age 20 -34 years, 5 vs. 2% developed diabetes, with similar findings for hyperlipidemia. A Veterans Administration dataset of medications administered during a 4-month period in 1999 compared 15,984 persons with schizophrenia treated with conventional antipsychotic drugs versus 22,648 treated with atypical antipsychotic agents: 1,207 persons received clozapine, 10,970 olanzapine, 9,903 risperidone, and 955 quetiapine. There were significant adverse effects of atypical antipsychotic agents in persons Ͻ60 years of age, although this was not found in analysis of older persons. Clozapine, olanzapine, and quetiapine were associated with increased diabetes risk, while this was not observed with risperidone (6) . Analysis of the U.K. general practice medical database from 1987 to 2000, including Ͼ30 million patient-years of observation, was used to compare olanzapine, risperidone, other atypical antipsychotic agents, and conventional antipsychotic medications, excluding persons with preexisting diabetes or hyperlipidemia (7) . Adjusted for treatment with ␣-and ␤-blockers, thiazide diuretics, corticosteroids, phenytoin, female sex hormones, and valproate, there was a 1.1-fold increased risk with conventional antipsychotics but a 6-fold increased risk with olanzapine. For hyperlipidemia, conventional antipsychotic agents led to 1.5-fold increased risk, olanzapine to a 5-fold increased risk, and ris-peridone to no increase in risk. In a 2-million member, managed-care system database, there was a 1.4-fold increase in diabetes risk with olanzapine, while risperidone, quetiapine, and conventional antipsychotic agents did not significantly increase diabetes (8) . Another study, which compared 19,153 persons receiving olanzapine with 14,793 receiving risperidone, showed a 1.2-fold increase in diabetes with the former agent, adjusting for age, sex, and haloperidol use, with particular increase in risk during the first 3 months of use (9) . Analysis of a pharmaceutical benefit plan dataset suggested increased diabetes risk with both conventional and atypical antipsychotic agents (10) . Newcomer presented a metaanalysis of 16 databases showing clozapine and olanzapine to increase diabetes risk 1.4-and 1.25-fold compared with risperidone.
In addition to increasing weight and being associated with increased risk of diabetes, Newcomer described a study in which triglyceride levels increased with olanzapine and quetiapine at 3 and 6 weeks, also with increase in fasting insulin, with a 26-week study comparing placebo, aripiprazole, and olanzapine showing the latter to be most likely to cause and to exacerbate the abnormalities of the metabolic syndrome. A joint panel of the ADA, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity has issued a consensus statement concluding that "there is considerable evidence" that treatment with atypical antipsychotic agents may lead to rapid weight gain and recommending that patients be monitored for this as well as for diabetes and CVD with personal and family history, as well as baseline and follow-up measurement of weight and height, waist circumference, blood pressure, and fasting glucose and lipids. The panel also concluded that the agents differ in their risk profiles, so that clozapine and olanzapine, while effective treatment options, are associated with greater risk of weight gain, diabetes, and lipid disorders (11) .
Retinopathy
Richard Hamman (Denver, CO) discussed the development of retinopathy in the Diabetes Prevention Program (DPP), noting that little is known about the time to onset of diabetic retinopathy in persons with new-onset type 2 diabetes and noting the paucity of studies among persons with IGT. There is evidence that retinopathy is preceded by ϳ5 years of hyperglycemia (12). Using the DPP database, it was possible to study the level of glycemia at which retinopathy occurs and the time course of development of retinopathy in early type 2 diabetes. A total of 3,234 persons with IGT and fasting blood glucose 95-125 mg/dl participated in the DPP. At the conclusion of the DPP, an outcome study was carried out in the 2,731 persons agreeing to participate, 1,854 without and 877 with diabetes. Retinal photos were performed in a subset of 12% of DPP participants. Retinopathy was found in some persons during the initial year following diabetes development. The development of "any retinopathy," excluding hemorrhage and exudates, occurred in 9.6 and 15.4% of persons without and with diabetes, with changes suggestive of diabetic retinopathy in 7.6 and 12.5%; 6.6 and 10.6 had microaneurysms, and 1% and 1.9 had mild to moderate nonproliferative diabetic retinopathy. Overall, diabetic retinopathy was seen in 7.6% of participants without diabetes, in 8.9% of those with diabetes for 0 -1 year, and in 13.5% at 1-2 years. There were no differences in risk factors among persons without diabetes who developed retinopathy. For those with diabetes, blood pressure levels were higher and HbA 1c (A1C) levels 6.26 vs. 6.06% among those with versus without diabetic retinopathy, respectively. Thus, retinopathy may be seen early in the course of type 2 diabetes at only modestly elevated levels of glycemia, arguing against the concept that this complication requires a long duration of diabetes with marked hyperglycemia. decreased VEGF expression. In vitro, exposure of vascular endothelial cells to high levels of glucose with C-peptide attenuated increased VEGF expression as well, suggesting this ␤-cell secretory product to have potential benefit in retinopathy, as has also been suggested for neuropathy and nephropathy. Growth factors also play a role in the development of diabetic nephropathy. Zhang et al. (abstracts 863 and 864) found that streptozotocin-induced diabetic rats had increased renal VEGF and intercellular adhesion molecule-1, as well as decreased renal levels of angiostatin, an antiangiogenic plasminogen fragment. They speculated that decreased matrix metalloprotease-2 results in decreased release of angiostatin, which may physiologically inhibit high glucose-induced expression of fibronectin, VEGF, and transforming growth factor-␤, contributing to inflammation and fibrosis. Pigment epitheliumderived factor, another angiogenic inhibitor, was also decreased by high glucose concentrations, another potential cause of transforming growth factor-␤ overexpression and fibronectin production, contributing to glomerular mesangial expansion.
Sun et al. (abstract 907) reported that aspirin in anti-inflammatory doses prevented the development of acellular capillaries in the retina of streptozotocininduced diabetic rats, without an effect of clopidogrel, an inhibitor of ADP-induced platelet aggregation, and without change in prostaglandin E2 levels, suggesting the mechanism to involve neither platelet effects nor change in prostaglandin levels. Zheng and Kern (abstract 929) administered aspirin, sodium salicylate, or sulfasalazine to diabetic rats, all agents reducing retinal vascular cell death and acellular capillaries, with the authors suggesting an nuclear factor B-mediated effect. Kowluru and Basak (abstract 908) found that retinal levels of the mitochondrial enzyme superoxide dismutase were inhibited ϳ30% in streptozotocininduced diabetic rats, with a three-to fourfold increase in apoptotic capillary cells and acellular capillaries; these abnormalities were prevented by dietary ␣-lipoic acid supplementation. Pavkov et al. (abstract 1066) followed 1,926 Pima Indians with diabetes for a mean of 13.7 years, reporting a 7.5-fold greater age-and sex-adjusted likelihood of ESRD among those developing diabetes at age Ͻ20 than at Ն20 years. Mortality was 2.7-and 1.9-fold greater for the younger-and older-onset diabetes groups than for 3,053 persons without diabetes. Boright et al. (abstract 845) studied apolipoprotein E polymorphisms in the 14-year DCCT/EDIC follow-up of 1,347 Caucasian persons with type 1 diabetes, finding that the T/T and T/C genotypes of the marker rs7412 were associated with 44% greater likelihood of development of persistent microalbuminuria than the C/C genotype, indicating an association with the e2 haplotype, although this was not significant in multivariate analysis with triglyceride, total cholesterol, and HDL. , systolic-diastolic 23%, and isolated systolic 56% of hypertension, but the likelihood of the three hypertension types was increased 11-, 5-, and 2-fold, respectively, in persons with versus without metabolic syndrome. Diastolic hypertension, although less common, may then be particularly associated with metabolic syndrome. Landsman and Alexander (abstract 646) used Third NHANES data to assess the relationship of diabetes, metabolic syndrome, and CRP to CHD among persons aged Ն50 years, showing CHD in 8 and 9% and CRP Ͼ3 mg/l in 25 and 25% of those with and without diabetes without metabolic syndrome, but, in CHD, in 19 and 14% of those with and without diabetes with metabolic syndrome and elevated CRP in 48 and 44% of those two groups. Among those with CRP Ͼ3 mg/l, 22% of those with diabetes, and 14% of those without diabetes had CHD. For those with metabolic syndrome without diabetes, the prevalence of CHD was 14 vs. 12% for high versus low CRP; for those with both metabolic syndrome and diabetes, the prevalence of CHD was 22 vs. 16% for high versus low CRP.
Several additional potential CVD risk factors were presented in other studies. Watanabe et al. (abstract 648) studied 12 persons with type 2 diabetes during a hyperinsulinemic-euglycemic clamp, showing increase in QT dispersion, the difference between the maximum and the minimum QT interval on a 12-lead electrocardiogram, a measure of the spatial inhomogeneity of cardiac repolarization, while there was no change in the coefficient of variation of RR intervals, a measure of cardiac autonomic neuropathy, and no association of the increase in QT dispersion with fall in serum potassium. Ljubic et al. (abstract 670) randomized 283 persons with type 2 diabetes to a 1-year period of treatment with atorvastatin, simvastatin, pravastatin, lisinopril/ losartan, aspirin, or a control group receiving none of these. CRP levels decreased with atorvastatin, simvastatin, and lisinopril/losartan; homocysteinewith simvastatin and pravastatin; and fibrinogen only with atorvastatin. Hermans et al. (abstract 679) assessed variants of the C 677 T methylene-tetrahydrofolate reductase gene polymorphism in 133 type 2 diabetic persons with homocysteine Ͼ12 mol/l, finding 55 with the CT and 25 with the TT genotype, with a 23% prevalence of stroke, while only 6% of the 53 with the CC genotype had had this complication, although the homocysteine levels did not differ between the three groups. Lin et al. (abstract 672) reported that plasma cardiotrophin-1, a newly isolated cytokine related to interleukin-6 that induces cardiac myocyte hypertrophy, was 31, 100, and 269 pg/ml in nondiabetic, type 2 diabetic normotensive, and type 2 diabetic hypertensive persons, correlating in multivariate analysis with blood pressure and with apolipoprotein B. Keenan et al. (abstract 727) performed a 10-cM genome screen on 177 diabetic and 317 nondiabetic family members for linkage with CRP and interleukin-6, both showing higher levels in persons with diabetes and both showing significant heritability; with gene linkages found on chromosomes 1q41 for interleukin-6 and 5p15 for CRP.
Avignon et al. (abstract 674) studied 20 type 2 diabetic persons with asymptomatic angiographically proven coronary disease and 20 age-, sex-, and duration-matched type 2 diabetic persons with negative exercise electrocardiogram and myocardial scintigraphy, showing association of coronary disease with plasma levels of osteoprotegerin, an inhibitor of osteoclast formation that may play a role in atherosclerosis. Young et al. (abstract 688) reported that of 236 asymptomatic persons with type 2 diabetes, 15% had "minor T-wave abnormality," which was associated with a 2.6-fold increase in the likelihood of the presence of reversible myocardial perfusion imaging defect, suggesting silent myocardial ischemia. The presence of T-wave abnormality had a 26% sensitivity, 88% specificity, positive predictive value of 30%, and negative predictive value of 85% in the population studied. Abnormal Valsalva ratio, a measure of cardiac autonomic neuropathy, was also significant in multivariate analysis, predicting a fivefold increase in likelihood of silent ischemia. Moriaj et al. (abstract 692) studied 170 type 2 diabetic persons, finding a 2.2-fold increase in CVD risk for those who were Helicobacter pylori positive, associated with an HDL cholesterol of 50 vs. 54 mg/dl in those who did not have serologic evidence of infection, with antibiotic treatment associated with 9.4% lowering of total cholesterol. Leitão et al. (abstract 838) studied 1,349 persons with type 2 diabetes, finding cigarette use to be associated with increased coronary disease, despite lower weight and blood pressure. Noninvasive CVD assessment. In a study of 335 nondiabetic MexicanAmerican persons whose parents had CAD, compared with 146 spouses without such history, Quinones et al. (abstract 691) reported that premature parental CAD (before age 55 years for fathers or 65 for mothers) was associated with carotid intima-media thickness (IMT) of 0.670 vs. 0.636 mm in those without such parental history. Fasting insulin was a sig- Metabolic syndrome increased the likelihood of stroke 23-fold, ischemic heart disease 2.4-fold, peripheral arterial disease 7.3-fold, and retinopathy 3.7-fold, although the authors recognized that one cannot determine from these data whether the increased risk is related to insulin resistance or rather to the effect of the various risk factors. Penno et al. (abstract 862) studied 978 persons with type 1 diabetes, finding 13% with metabolic syndrome, with hypertension the most common defining abnormality. Microalbuminuria was present in 27% of those with compared with 18% of those without metabolic syndrome, as well as macroalbuminuria in 21 vs. 5%, with the syndrome also correlating with retinopathy.
Maahs et al. (abstract 682) measured coronary artery calcium (CAC) with computerized tomography twice over a mean of 2.5 years in 466 type 1 diabetic patients. Among 81 persons with elevated urinary albumin, worsening CAC was 4.3-fold more likely in those not receiving ACE inhibitor or ARB treatment but was not significantly increased for those receiving this treatment. Other predictors of CAC progression were age, diabetes duration, baseline CAC, HDL cholesterol, and systolic blood pressure. Wadwa et al.
(abstract 725), from the same group, reported that arterial stiffness was associated with blood pressure, age, diabetes duration, and A1C but not with CAC, suggesting the latter to reflect a different aspect of coronary disease.
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